Intérêt de la résection complémentaire (ou « second look ») pour les carcinomes urothéliaux de vessie classés pTa haut grade

[1]  Shahrokh F. Shariat,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.

[2]  E. Compérat,et al.  RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU — Actualisation 2018—2020 : tumeurs de la vessie , 2018, Progrès en Urologie.

[3]  E. Compérat,et al.  Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeurs de la vessie , 2018, Progrès en Urologie.

[4]  R. Sylvester,et al.  Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. , 2018, European urology.

[5]  A. Masson-Lecomte,et al.  [French ccAFU guidelines - Update 2018-2020: Bladder cancer]. , 2018, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[6]  J. Catto,et al.  Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. , 2017, European urology focus.

[7]  P. Brenner,et al.  Repeat transurethral resection for non‐muscle‐invasive bladder cancer: a contemporary series , 2016, BJU international.

[8]  F. Cheng,et al.  Relevance of Repeat Transurethral Resection of the Bladder for High Grade pTa Bladder Cancer: A Review , 2016 .

[9]  L. Collette,et al.  EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. , 2016, European urology.

[10]  X. Zu,et al.  A preoperative marker panel for the prediction of residual tumor and the decision making for repeat transurethral resection. , 2015, Urologic oncology.

[11]  Yonghui Chen,et al.  Repeated transurethral resection for non-muscle invasive bladder cancer. , 2015, International journal of clinical and experimental medicine.

[12]  J. Dobruch,et al.  Clinical value of transurethral second resection of bladder tumor: systematic review. , 2014, Urology.

[13]  J. Patard,et al.  Faut-il proposer une seconde résection systématique pour toutes les tumeurs de vessie n’infiltrant pas le muscle vésical à risque élevé ? , 2014 .

[14]  J. Patard,et al.  [Should we propose a systematic second transurethral resection of the bladder for all high-risk non-muscle invasive bladder cancers?]. , 2014, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[15]  Dong Liu,et al.  Re-Transurethral Resection Treatment for Non-invasive Bladder Tumor , 2014, Cell Biochemistry and Biophysics.

[16]  S. Holmäng.  High-grade non-muscle-invasive bladder cancer: Is re-resection necessary in all patients before intravesical bacillus Calmette–Guérin treatment? , 2013, Scandinavian journal of urology.

[17]  A. S. Brandt,et al.  Second Transurethral Resection after Ta High-Grade Bladder Tumor: A 4.5-Year Period at a Single University Center , 2013, Urologia Internationalis.

[18]  J. M. Gaya,et al.  La re-resección transuretral puede no ser necesaria en todos los tumores vesicales no músculo-invasivos de alto grado , 2012 .

[19]  M. Yao,et al.  An evaluation to define the role of repeat transurethral resection in a treatment algorithm for non-muscle-invasive bladder cancer , 2012, Indian journal of urology : IJU : journal of the Urological Society of India.

[20]  N. Vasdev,et al.  The Role of Early Re-Resection in pTaG3 Transitional Cell Carcinoma of the Urinary Bladder , 2011 .

[21]  A. Hoznek,et al.  The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. , 2010, The Journal of urology.

[22]  R. Sylvester,et al.  Prognostic Factors in Non–Muscle-Invasive Bladder Tumors: I. Clinical Prognostic Factors: A Review of the Experience of the EORTC Genito-Urinary Group II. Biologic Prognostic Markers , 2007 .

[23]  H. Herr,et al.  A re‐staging transurethral resection predicts early progression of superficial bladder cancer , 2006, BJU international.

[24]  M. Grimm,et al.  Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. , 2003, The Journal of urology.

[25]  R Sylvester,et al.  The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. , 2000, The Journal of urology.

[26]  H. Akaza,et al.  Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results , 1995 .